• GW Malignant Hematology Program
  • Comprehensive Cancer Care
  • The GW Cancer Center Malignant Hematology program ¬†specializes in the diagnosis and treatment of various blood cancers and autoimmune disorders. For more information call (202) 741-2210.¬†

Title Description
A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients-the INSIGHT-MM study

The objective of this study is to describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, therapeutic regimen chosen, and clinical outcomes in patients with newly diagnosed multiple myeloma and patients with relapsed/refractory multiple myeloma.

New treatment approach for multiple myeloma

CC4047-MM-007: A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidamide, Bortezomib and Low-Dose Dexamethasone versus Bortezomib and Low-Dose Dexamethasone in subjects with Relapsed or Refractory Multiple myeloma The purpose of this study is to see how well the combination of pamalidomide, bortezomib and dexamethasone works compared to the combination of bortezomib and dexamethasone.

X05383: Retrospective Study to Evaluate the Incidence and Severity of Peripheral Neuropathy in Relapsed/Refractory Mulitple Myeloma Patients Retreated with Bortezomib

Determining the incidence and change in severity of peripheral neuropathy upon retreatment of multiple myeloma patients with bortezomib as compared to initial bortezomib treatment

GWCC Malignant Hematology Program
22nd & I Street, NW First Floor
Washington , DC
United States

Schedule an Appointment

202-741-2210